Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Front-line immunosuppressive treatment of acquired aplastic anemia

    ... 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the presence of a ...

    Research Article last updated 01/02/2013 - 2:48pm.

  2. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... To date, all patients maintained long-term transfusion independence (over 4.5 years) while receiving oral lenalidomide therapy, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... Lenalidomide leads to high rates of erythroid transfusion independence in low and intermediate-1 risk International Prognostic ...

    Research Article last updated 11/05/2012 - 9:37am.

  4. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during ... for TD were met and continued until transfusion independence (TI). Kaplan-Meier statistics and Cox Proportional Hazard ...

    Research Article last updated 05/26/2015 - 11:49am.

  5. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... rate with an additional 49% stable disease, 34% transfusion independence ) included 1 complete response lasting >1 year. No responses ...

    Research Article last updated 08/04/2014 - 8:28am.

  6. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in the lenalidomide 10 mg ... benefits and acceptable safety profile of lenalidomide in transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with ...

    Research Article last updated 07/29/2014 - 12:12pm.

  7. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria

    ... to response criteria. Complete response was defined as transfusion independence with normal hemoglobin for age/sex, absence of ...

    Research Article last updated 11/05/2012 - 10:28am.

  8. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic syndromes ...

    Research Article last updated 04/24/2012 - 2:47pm.

  9. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... the US Food and Drug Administration (FDA) for treatment of transfusion-dependent lower-risk myelodysplastic syndrome patients with ... was based on high rates of prolonged transfusion independence and complete cytogenetic response in this subset. In ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall survival versus LDara-C in ...

    Research Article last updated 10/11/2011 - 5:58pm.